Details for New Drug Application (NDA): 216266
✉ Email this page to a colleague
The generic ingredient in LISDEXAMFETAMINE DIMESYLATE is lisdexamfetamine dimesylate. Seventeen suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
Summary for 216266
Tradename: | LISDEXAMFETAMINE DIMESYLATE |
Applicant: | Prinston Inc |
Ingredient: | lisdexamfetamine dimesylate |
Patents: | 0 |
Pharmacology for NDA: 216266
Physiological Effect | Central Nervous System Stimulation |
Medical Subject Heading (MeSH) Categories for 216266
Suppliers and Packaging for NDA: 216266
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LISDEXAMFETAMINE DIMESYLATE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 216266 | ANDA | Solco Healthcare US,LLC | 43547-602 | 43547-602-10 | 100 CAPSULE in 1 BOTTLE (43547-602-10) |
LISDEXAMFETAMINE DIMESYLATE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 216266 | ANDA | Solco Healthcare US,LLC | 43547-603 | 43547-603-10 | 100 CAPSULE in 1 BOTTLE (43547-603-10) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 10MG | ||||
Approval Date: | Aug 25, 2023 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 20MG | ||||
Approval Date: | Aug 25, 2023 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 30MG | ||||
Approval Date: | Aug 25, 2023 | TE: | AB | RLD: | No |
Complete Access Available with Subscription